Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Not yet recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 3Thoracic 2Other solid neoplasm 2Breast 1

Conditions

Solid Tumor 1MSI-H 1

Interventions

pembrolizumab 9Specimen Handling 7tislelizumab 6Pemetrexed 6Cisplatin 6Carboplatin 6fludarabine 5atezolizumab 5Interviews as Topic 5Injections 5Cyclophosphamide 5Bevacizumab 5Platinum 4Fluorouracil 4Educational Status 4Biopsy 4Standard of Care 3Practice Guidelines as Topic 3Nivolumab 3Methods 3Magnetic Resonance Spectroscopy 3Early Intervention, Educational 3Cetuximab 31,2-diaminocyclohexaneplatinum II citrate 3sintilimab 2sacituzumab govitecan 2fludarabine phosphate 2X-Rays 2Trastuzumab 2Radiotherapy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
sintilimab × Other solid neoplasm × 30 days × Clear all
NCT05890742 2026-05-28

A Clinical Trial Evaluating the Efficacy and Safety of IBI310 in Combination With Sintilimab, for Neoadjuvant Treatment of MSI-H/dMMR Resectable Colon Cancer

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3 Active not recruiting
453 enrolled
Other solid neoplasm

MSI-H

NCT07612137 2026-05-28

Study of IBI3005 Combination Therapy in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors

Innovent Biologics (Suzhou) Co. Ltd.

Phase 1/2 Not yet recruiting
282 enrolled
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡